11a

11a is a small molecule phosphodiesterase (PDE) inhibitor currently under development by Goldenrod Therapeutics. It is in the preclinical stage of development, specifically demonstrating in vivo activity for the treatment of Substance Use Disorder and Parkinson's Disease. As a phosphodiesterase inhibitor, 11a is designed to modulate intracellular signaling by preventing the degradation of cyclic nucleotides such as cAMP or cGMP, which play critical roles in neurotransmission and neuroprotection. The drug is part of a pipeline of PDE inhibitors being explored by Goldenrod Therapeutics for various central nervous system and inflammatory disorders.